A Study of HDM2020 in Patients With Advanced Sq-NSCLC

Summary

The goal of this clinical trial is to learn if the study drug can treat in advanced squamous non-small cell lung cancer(NSCLC) patients. The main questions it aims to answer are: Is the drug safe and tolerable? Does the drug show antitumor activity? Participants will receive the study drug once(D1) or twice(D1.D8) every three weeks, and undergo imaging-based efficacy assessments every six weeks.

Timeline

Start

2026-04-01

Primary completion

2027-01-31

Completion

2027-11-03

Drugs

Indications